Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Sector news Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
05/07 REGENERON PHARMACEUTICALS : shares poised for rebound - Barron's
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
03/31 ACTELION : J&J declares Actelion tender offer a success, sees closing in second ..
03/31DJJOHNSON & JOHNSON : Says Tender Offer to Buy Actelion Successful
03/30 China's Creat makes 1.2 billion euro bid for German blood plasma firm
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/14 AstraZeneca ovarian cancer drug slows disease markedly in study
03/09 Bull market turns 8 - historical facts and figures
03/09 Germany's Merck well advanced in talks to sell biosimilars unit
03/08 Compare and contrast - Trump's tweets vs private comments to CEOs
03/07 Drugmaker shares slip as Trump tweets about pricing system
03/06DJINCYTE : Race Tightens for Next Wave of Cancer Drugs
03/02DJACTELION : Founders Start New Biotech, With J&J's Backing
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
02/08DJSANOFI : Seeks Cure for FDA Concerns at French Factory -- Update
02/08DJSanofi Net Profit More Than Doubles -- Update
02/08DJGILEAD SCIENCES : Posts Profit, Revenue Declines -- Update
02/07DJGilead Posts Profit, Revenue Declines
02/06 New GlaxoSmithKline CEO prepares for R&D choices, potential deals
02/03DJAMGEN : Good News for Amgen Is God News for Biotech
02/03DJAMGEN : Correction to Amgen Repatha Story
02/02DJAMGEN : Sees Positive Results in Repatha Study -- 2nd Update
1  2  3  4  5  6  7  8  9  10Next
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Financials ($)
Sales 2017 1,85 M
EBIT 2017 -100 M
Net income 2017 -66,8 M
Debt 2017 2,93 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 202x
EV / Sales 2018 185x
Capitalization 370 M
More Financials
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
PURETECH HEALTH PLC1.80%366
INCYTE CORPORATION37.73%27 528
QUINTILES IMS HOLDINGS..10.19%18 382
LONZA GROUP AG23.08%15 234
CELLTRION, INC.--.--%10 254
SEATTLE GENETICS, INC.26.34%9 492
ALKERMES PLC3.83%8 934
QIAGEN NV12.17%7 527
ALNYLAM PHARMACEUTICAL..99.97%6 372
IONIS PHARMACEUTICALS ..-5.62%5 549
UNITED THERAPEUTICS CO..-15.32%5 523
ICON PLC19.57%4 810
PRA HEALTH SCIENCES IN..29.72%4 440
GALAPAGOS22.10%4 344
CHARLES RIVER LABORATO..20.36%4 306
BIO-TECHNE CORP8.00%4 119
PAREXEL INTERNATIONAL ..21.10%4 026
EXACT SCIENCES CORPORA..146.71%3 536
ACADIA PHARMACEUTICALS..-4.47%3 419
BB BIOTECH AG-0.27%3 125
INC RESEARCH HOLDINGS ..6.37%3 041
Sector Biotechnology & Medical Research - NEC